[

gates foundation

]

Latest from gates foundation

US vaccine hopeful of using Gates Foundation cash to prepare for human trial

Harvard University scientist Luk Vandenberghe and University of Pennsylvania gene therapy head James Wilson said primate safety and efficacy tests have proven promising for their single-dose candidate, targeted for room-temperature storage.
Their candidate relies on an adeno-associated virus (AAV), deemed harmless to humans, to deliver DNA fragments from the new coronavirus, telling human cells to make a protein that provokes an immune response. (Representative Image)(AP)
Their candidate relies on an adeno-associated virus (AAV), deemed harmless to humans, to deliver DNA fragments from the new coronavirus, telling human cells to make a protein that provokes an immune response. (Representative Image)(AP)
Published on Jan 29, 2021 06:01 PM IST
Copy Link
Reuters |
Story Saved
×
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Tuesday, May 24, 2022